Abstract: Provided herein are methods, compositions, and kits for the treatment of an enteric nervous system disorder. Such methods may comprise administering to a subject an effective amount of a phenothiazine compound, a peripherally restricted dopamine decarboxylase inhibitor, and/or a peripherally restricted dopamine D2 receptor antagonist that does not substantially inhibit hERG channels.
Abstract: One aspect of the disclosure relates to the use of derivatives of dichlorophenyl urea for treating cancers.
Type:
Grant
Filed:
June 4, 2016
Date of Patent:
November 7, 2017
Assignee:
CITY OF HOPE
Inventors:
Samuel Rahbar, James L. Figarola, Christopher Lincoln, David Horne, Rachael Mooney, Monika Polewski, George Somlo, Lixin Yang, Sanjay Awasthi, Sharad Singhal, Jyotasana Singhal
Abstract: This application discloses compounds according to generic Formula (I): wherein all variables are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are useful for the treatment of oncological, auto-immune, and inflammatory diseases caused by aberrant B-cell activation. Also disclosed are compositions containing compounds of Formula I and at least one carrier, diluent or excipient.
Abstract: A pharmaceutical composition for parenteral administration containing the active ingredient 1-adamantylethyloxy-3-morpholino-2-propanol, or pharmaceutically acceptable salts thereof, in a concentration range of from 3 to 100 mg/ml for the treatment of cardiovascular disease.
Abstract: A hormone delivery system and method are provided for administering bioidentical human hormones using a combination of modalities for the treatment of human physiological conditions.
Type:
Grant
Filed:
August 8, 2016
Date of Patent:
October 24, 2017
Assignee:
Baucom Institute for Longevity and Life Enhancement, Inc.
Abstract: The invention provides methods for muscle repair or regeneration comprising administering therapeutically effective amounts of RAR agonists or stem cells that are pretreated with contact with a RAR agonist to a subject at a site of muscle damage. Additionally, the invention provides compositions comprising RAR agonist treated stem cells and methods of use of said cells for muscle repair or regeneration. In one embodiment, the stem cells are mesenchymal stem cells. In one embodiment, the RAR agonist is an RAR? agonist. In one embodiment, administration of the RAR agonist is begun during a period of increased endogenous retinoid signaling in the subject resulting from incurrence of the damaged muscle tissue.
Abstract: This invention provides an oral dosage regimen for the treatment of depression, a pharmaceutically acceptable medication dispensing package containing multiple dosage units of medicaments comprising an oral dosage regimen of D-cycloserine for the treatment of depression, a pharmaceutical composition comprising D-cycloserine formulated for oral administration providing a dosage of 1000 mg/day alone or in combination with antidepressant agents and uses thereof.
Abstract: Provided herein are methods for preventing or alleviating the symptoms of and inflammation associated with inflammatory diseases and conditions of the gastrointestinal tract, for example, those involving the esophagus. Also provided herein are pharmaceutical compositions useful for the methods of the present invention.
Type:
Grant
Filed:
January 3, 2014
Date of Patent:
October 10, 2017
Assignees:
The Regents of the University of California, Meritage Pharma, Inc.
Inventors:
Ranjan Dohil, John Bastian, Seema Aceves, Elaine Phillips, Malcolm Hill
Abstract: The present invention is directed to a liquid formulation comprising levothyroxine or a pharmaceutically acceptable salt thereof. The formulation of the present invention includes tromethamine, sodium iodide, and water and has a pH of about 9.0 to about 11.5. The liquid formulation according to the invention is stable and ready-to-use.
Abstract: A method of preventing or treating a disease associated with demyelination of a nerve cell in a mammal, a method of promoting remyelination or suppressing demyelination of a nerve cell in a mammal, and a method of reducing expression of PMP22 in a nerve cell of a mammal by administration of 2,5-dihydroxybenzenesulfonic acid or a pharmaceutically acceptable salt or solvate thereof.
Type:
Grant
Filed:
July 5, 2016
Date of Patent:
October 10, 2017
Assignees:
SAMSUNG ELECTRONICS CO., LTD., KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION
Inventors:
Yunil Lee, Suhyun Kim, Haechul Park, Sangchul Park
Abstract: Complexes of neridronic acid, in an acid or a salt form, with amino acids, can be used to treat or alleviate pain or related conditions, such as complex regional pain syndrome.
Abstract: The present invention relates to the use of a 1,4-benzoquinone derived compound for the treatment of a disease or condition that is associated with peroxisome proliferator activated receptor (PPAR) activity in a mammal.
Abstract: The present invention relates to lower dosage strength pernasal testosterone gel formulations for intranasal administration and treatment methods for using the lower dosage strength pernasal testosterone gel formulations for treating a female subject with anorgasmia and/or hypoactive sexual desire disorder.
Type:
Grant
Filed:
May 14, 2012
Date of Patent:
September 12, 2017
Assignee:
Acerus Pharmaceuticals SRL
Inventors:
Wayne Kreppner, Siobhan Fogarty, Werner Oberegger, Paul Maes
Abstract: The present invention relates to new medical uses of morphinans such as naltrexone, nalmefene and their related derivatives. The present invention relates to Toll-like receptor 4 (TLR4) antagonist compounds, and pharmaceutical formulations thereof, and use thereof for prevention and treatment of autoimmune liver diseases including but not limited to autoimmune hepatitis.
Type:
Grant
Filed:
March 23, 2016
Date of Patent:
September 12, 2017
Assignee:
TaiwanJ Pharmaceuticals Co., Ltd.
Inventors:
Peter J S Chiu, Mei-chi Hsu, Ying-Chu Shih, Edwin S C Wu
Abstract: The present invention relates to the use of flecainide as an anti-connexin agent. This anti-connexin agent is advantageously used to potentiate the therapeutic effect of various psychotropic drugs. More specifically, the invention provides a combination product containing flecainide and modafinil.
Type:
Grant
Filed:
July 24, 2014
Date of Patent:
September 5, 2017
Assignee:
COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES
Abstract: In one aspect, the invention relates to compounds having a general structure: and methods of using same to modulate calcium release. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
Type:
Grant
Filed:
October 14, 2011
Date of Patent:
September 5, 2017
Assignee:
University of Utah Research Foundation
Inventors:
Eric W. Schmidt, Zhenjian Lin, Rowena R. Antemano, Alan Light, Baldomero M. Olivera, Gisela P. Concepcion
Abstract: The present invention relates to a method of pre-rinsing laundry and treating other surfaces employing a composition that can kill bedbug eggs. The composition includes a fatty alcohol and an alcohol ethoxylate.
Type:
Grant
Filed:
November 20, 2012
Date of Patent:
August 29, 2017
Assignee:
Ecolab USA Inc.
Inventors:
Kim R. Smith, Erik C. Olson, Yvonne M. Killeen, Victor F. Man, Joelle F. Olson, Erin F. Loosbrock
Abstract: The present disclosure relates to solid dosage forms comprising antiviral compounds and methods of using such dosage forms to treat antiviral infection.
Type:
Grant
Filed:
March 18, 2016
Date of Patent:
August 29, 2017
Assignee:
AbbVie Inc.
Inventors:
Jonathan M. Miller, John B. Morris, Nancy E. Sever, Eric A. Schmitt, Ping X. Gao, Yi Shi, Yi Gao, Bernd Liepold, Anna Moosmann, Mirko Pauli, Fatih Durak, Thomas Kessler, Peter Hoelig, Karin Rosenblatt, Drazen Kostelac, Rajeev Gokhale, Mark Costello, Carl Knable
Abstract: A method for treating an inflammation or lesion caused by herpes virus, comprising topically applying to said inflammation or lesion a composition comprising or consisting essentially of a C1 to C3 monohydroxy alcohol or a C2 to C4 diol and a sufficient amount of an acid to adjust the pH of the composition to below 4.6. Topical administration of the composition is preferred and is effective in treating lesions associated infections by viruses such as Herpes simplex. Nasal deliverable forms are effective in treating symptoms due to viruses that cause the common cold. Pharmaceutical compositions for use in the present method are provided.
Type:
Grant
Filed:
October 30, 2014
Date of Patent:
August 22, 2017
Assignee:
TOPICAL REMEDY, LLC
Inventors:
Thomas W. Konowalchuk, Jack Konowalchuk
Abstract: An agent for treating ischemia/reperfusion injury, including a therapeutically effective amount of a p53 agonist compound including a cis-imidazoline structure.